KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

VEPESID 50 MG CAPSULES

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

50 MG

 

GENERIC NAME:

ETOPOSIDE

 

MANUFACTURER:

BRISTOL MYERS SQUIBB

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

D

 

INDICATIONS:

Carcinoma, lung

Carcinoma, testicular

 

SIDE EFFECTS:

Anemia

leukopenia

thrombocytopenia

Stomatitis

Anaphylaxis

chemical phlebitis

neurotoxicity

skin rash or itching

Loss of appetite

nausea and vomiting

Central nervous system (CNS) toxicity

diarrhea

Alopecia

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Bone marrow depression

>> Chickenpox, existing

>> Herpes zoster

Hepatic function impairment

>> Infection

Renal function impairment

Sensitivity to etoposide

 

ADULT DOSE:

Small cell lung carcinoma-Oral, 70 mg (base) per square meter of body surface area (rounded to the nearest 50 mg) per day for four days to 100 mg per square meter of body surface area (rounded to the nearest 50 mg) per day for five days, repeated every three to four weeks.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Dosage has not been established.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

 

 

PREVIOUS

  

NEXT